Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO--(BUSINESS WIRE)--May 10, 2024-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer's Board of Directors approved the grant, effective May 8, 2024, to three new non-executive employees of non-qualified stock option awards to purchase up to an aggregate of 323,000 shares of the Company's common stock under the Gossamer Bio, Inc. 2023 Employment Inducement Incentive Award Plan ("2023 Inducement Plan"). The awards were granted as an inducement material to the employees entering into employment with Gossamer in accordance with Nasdaq Listing Rule 5635(c)(4).
圣地亚哥--(美国商业资讯)--2024年5月10日-- Gossamer Bio, Inc. (Nasdaq: GOSS) 是一家临床阶段的生物制药公司，专注于开发和商业化用于治疗肺动脉高压 (PAH) 和与间质性肺病 (PH-ILD) 相关的肺动脉高压 (PH-ILD) 的肺动脉高压。该公司今天宣布，戈萨默董事会薪酬委员会批准了对三名非合格股票期权新非执行员工的补助金，该补助金自2024年5月8日起生效奖励购买Gossamer Bio, Inc.旗下最多32.3万股公司普通股2023 年就业激励奖励计划（“2023 年激励计划”）。根据纳斯达克上市规则5635（c）（4），这些奖励是作为激励在Gossamer工作的员工的激励材料而颁发的。
The options have an exercise price of $0.755 per share, which is equal to the closing price of Gossamer's common stock as reported by The Nasdaq Global Select Market on May 8, 2024. The options have a ten-year term and will vest over four years, with 25% vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the shares vesting in a series of 36 successive monthly installments thereafter, subject to each employee's continued employment with Gossamer on such vesting dates. The options are subject to the terms and conditions of the 2023 Inducement Plan and the terms and conditions of a stock option agreement covering the grants.
这些期权的行使价为每股0.755美元，等于纳斯达克全球精选市场于2024年5月8日公布的戈萨默普通股的收盘价。这些期权的期限为十年，将在四年内归属，其中25％在适用的归属开始日期一周年之际归属，其余股份将分36次连续每月分期归属，前提是每位员工在该归属日期继续在Gossamer工作。期权受2023年激励计划的条款和条件以及涵盖补助金的股票期权协议的条款和条件的约束。
About Gossamer Bio
关于 Gossamer Bio
Gossamer Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension. Its goal is to be an industry leader in, and to enhance the lives of patients living with, pulmonary hypertension.
Gossamer Bio是一家临床阶段的生物制药公司，专注于用于治疗肺动脉高压的血清替尼的开发和商业化。其目标是成为肺动脉高压的行业领导者，并改善肺动脉高压患者的生活。
View source version on businesswire.com: https://www.businesswire.com/news/home/20240510801953/en/
For Investors and Media:
Bryan Giraudo, Chief Operating Officer and Chief Financial Officer
Gossamer Bio Investor Relations
ir@gossamerbio.com
对于投资者和媒体：
布莱恩·吉罗多，首席运营官兼首席财务官
Gossamer Bio 投资者关系
ir@gossamerbio.com
Source: Gossamer Bio, Inc.
来源：Gossamer Bio, Inc.